Business Context and Reporting Period
BioMarin Pharmaceutical Inc. (BMRN) is a global rare disease biotechnology company focused on delivering medicines for genetically defined conditions. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as a single business segment and reported 192,114,344 shares of common stock outstanding as of October 23, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $776.1 million | $745.7 million | $2,346.7 million | $2,106.6 million |
| Net Income (Loss) | $(30.7) million | $106.1 million | $395.5 million | $301.9 million |
| Diluted EPS | $(0.16) | $0.55 | $2.04 | $1.56 |
| Gross Margin | 81.9% | 74.7% | 81.2% | 78.9% |
| Operating Cash Flow (9M) | $728.4 million | $387.2 million | N/A | N/A |
| Cash & Investments (Total) | $1,990.7 million | N/A | N/A | N/A |
| Convertible Debt (Principal) | $600.0 million | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4.1% in Q3 2025 compared to Q3 2024, driven primarily by higher sales volumes of VOXZOGO (achondroplasia) and PALYNZIQ (PKU). This was partially offset by lower sales of ALDURAZYME and NAGLAZYME due to order timing.
- Profitability Impact: The company reported a net loss of $30.7 million in Q3 2025, a reversal from the $106.1 million net income in Q3 2024. This was primarily due to a $221.0 million non-cash charge for acquired In-Process Research and Development (IPR&D) related to the July 2025 acquisition of Inozyme Pharma, Inc.
- R&D Expenses: R&D expenses surged to $409.5 million in Q3 2025 from $184.9 million in Q3 2024, largely attributable to the Inozyme IPR&D charge and increased spending on later-stage clinical programs.
- Liquidity: Cash and cash equivalents increased to $1.25 billion as of September 30, 2025, from $942.8 million at year-end 2024. Total cash, cash equivalents, and investments stood at $1.99 billion.
Guidance, Outlook, and Risks
- Strategic Acquisitions: BioMarin completed the acquisition of Inozyme Pharma for approximately $285 million (net of cash) to add BMN 401, a late-stage enzyme replacement therapy for ENPP1 deficiency, to its portfolio.
- Portfolio Strategy: In October 2025, the company announced plans to explore divestiture options for ROCTAVIAN (hemophilia A), including out-licensing, while continuing commercial availability in the U.S., Italy, and Germany.
- Product Updates: New data presented in September 2025 showed VOXZOGO improves spinal morphology in children with achondroplasia. PALYNZIQ Phase 3 data in adolescents demonstrated statistically significant blood phenylalanine lowering.
- Regulatory & Tax Risks: The company is evaluating the impact of the "One Big Beautiful Bill" (OBBB) Act signed in July 2025, which includes tax reform provisions. Additionally, a U.S. government shutdown beginning October 1, 2025, poses risks to FDA review timelines.
- Debt Obligations: The company has $600 million in 1.25% senior subordinated convertible notes due in May 2027. Management believes current cash flows and investments are sufficient for liquidity needs for at least the next 12 months.
Investor Verification Checklist
- IPR&D Charge Impact: Verify the long-term value realization of the $221 million Inozyme IPR&D charge and the development timeline for BMN 401.
- ROCTAVIAN Divestiture: Monitor progress on the announced exploration of divestiture options for ROCTAVIAN and potential impact on future revenue streams.
- Government Shutdown Effects: Assess the potential delay in FDA regulatory reviews due to the October 2025 government shutdown.
- Generic Competition: Review the ongoing impact of generic competition on KUVAN revenues and pricing strategies.
- Debt Maturity: Confirm the company's strategy for the $600 million convertible note maturity in May 2027 (conversion vs. cash repayment).